DP3-R
DP3-R
Research Use Only
All products are intended solely for laboratory research and are not for human or animal consumption. These products are not drugs, foods, or cosmetics, and are not intended to diagnose, treat, cure, or prevent any disease. Purchasers must be 21 years or older. By purchasing, the buyer agrees to use these products in compliance with all applicable laws and regulations.
DP3-R Overview
DP3-R is a synthetic investigational peptide developed as a multi-pathway (triple receptor) agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptor pathways. It is studied for its potential effects on receptor-mediated signaling, molecular dynamics, and endocrine function in preclinical research models. By activating multiple target receptor subtypes, DP3-R is investigated for its relevance in endocrine and pathway-level research.
History
The development of DP3-R builds on years of research into peptide signaling. Early studies with single-pathway agonists established their role in downstream signaling and receptor activity. Subsequent research expanded to dual-agonist frameworks, paving the way for triple-target designs like DP3-R, which integrates three pathway targets in a single molecular structure. This multi-agonist approach reflects a direction in peptide research aimed at investigating broader receptor-mediated modulation in preclinical laboratory settings.
DP3-R Structure
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: 4845.44 g/mol
PubChem ID: 474492335
Research Findings
DP3-R has been examined in endocrine and systemic models, with studies highlighting its influence on receptor binding kinetics, downstream signaling cascades, lipid pathway dynamics, and integrated endocrine pathways. Research also points to its role in multi-system signaling and pathway characterization in preclinical and laboratory settings.
Key Areas of Research:
- Endocrine: Receptor binding, signaling cascades
- Pathway: Target subtypes, modulation, dynamics
- Vascular: Lipid pathways, hepatic signaling, markers
- Systemic: Multi-pathway signaling, pathway characterization
Together, these findings suggest broad experimental potential for DP3-R across endocrine, vascular, and systemic models. By engaging multiple pathway targets, it provides a versatile research platform for studying downstream signaling cascades and integrated molecular responses across diverse biological systems.
References
Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247.
Jastreboff, A.M., et al. (2023). Triple–hormone-receptor agonist for obesity — a phase 2 trial. New England Journal of Medicine, 389(6), 514–526.
Urva, S., Coskun, T., et al. (2022). A novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet, 400(10366), 1869–1881.